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Abstract
Background: A standardized regimen recommended by the World Health Organization for retreatment of active
tuberculosis (TB) is widely used, but treatment outcomes are suspected to be poor. We conducted a systematic review of
published evidence of treatment of patients with a history of previous treatment or documented isoniazid mono-resistance.
Methods and Findings: PubMed, EMBASE, and the Cochrane Central database for clinical trials were searched for
randomized trials in previously treated patients and/or those with with mono-resistance to isoniazid, published in English,
French, or Spanish between 1965 and June 2008. The first two sources were also searched for cohort studies evaluating
specifically the current retreatment regimen. In studies selected for inclusion, rifampin-containing regimens were used to
treat patients with bacteriologically confirmed pulmonary TB, in whom bacteriologically confirmed failure and/or relapse
had been reported. Pooled cumulative incidences and 95% CIs of treatment outcomes were computed with random effects
meta-analyses and negative binomial regression. No randomized trials of the currently recommended retreatment regimen
were identified. Only six cohort studies were identified, in which failure rates were 18%–44% in those with isoniazid
resistance. In nine trials, using very different regimens in previously treated patients with mono-resistance to isoniazid, the
combined failure and relapse rates ranged from 0% to over 75%. From pooled analysis of 33 trials in 1,907 patients with
mono-resistance to isoniazid, lower failure, relapse, and acquired drug resistance rates were associated with longer duration
of rifampin, use of streptomycin, daily therapy initially, and treatment with a greater number of effective drugs.
Conclusions: There are few published studies to support use of the current standardized retreatment regimen. Randomized
trials of treatment of persons with isoniazid mono-resistance and/or a history of previous TB treatment are urgently needed.
Please see later in the article for the Editors’ Summary.
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A key component of the directly observed treatment short-
course (DOTS) strategy of the World Health Organization (WHO)
is the use of a limited number of standardized regimens [1]. This
strategy ensures that treatment is always given with the same
number, dose, and type of medications—the simplicity enhances
access to treatment in resource-poor settings. A single 8-mo
‘‘retreatment’’ regimen (8 mo of isoniazid, rifampin, ethambutol,
with pyrazinamide added for the first 3 mo, and streptomycin
added for the first 2 mo—2SHRZE/1HRZE/5HRE) is recom-
mended for all patients with a history of previous treatment [1]
and is used in more than 90 countries [2].
This WHO retreatment regimen was initially designed for
resource-poor settings with low prevalence of initial drug resistance,
and for patients previously treated with a regimen that used rifampin
onlyforthefirst2 mooftherapy[3].Itwasbelievedthattheregimen
should be adequate for patients with mono-resistance, such as to
isoniazid. However, this regimen has been increasingly criticized
[4,5] because of poor results [2], particularly in settings where
prevalence of initial drug resistance is high [2,6] or rifampin is used
throughout initial therapy [7]. In light of these concerns, we have
conducted a systematic review of published evidence of treatment of
patients with a history of previous treatment or documented
isoniazid mono-resistance.
Review Questions
Our systematic review addressed two specific questions:
1. What are the rates of failure, relapse, and acquired drug
resistance with the currently recommended WHO retreatment
regimen—in randomized trials and cohort studies?
2. What treatment factors are associated with failure, relapse, and
acquired drug resistance in randomized trials of patients with
pretreatment resistance to isoniazid?
Methods
Search Strategy
As seen in Figure 1, we searched three electronic databases—
PubMed, EMBASE, and the Cochrane Central database—for
randomized controlled trials (RCTs) of treatment of patients with
previous TB treatment, or mono-resistance to isoniazid. The
search was restricted to studies published in English, French, or
Spanish between 1965 and June 2008. Our keywords included
tuberculosis or TB, retreatment or repeated therapy or previously
treated patients, and failure or relapse or drug resistance. To
identify additional relevant articles, we searched reference lists of
identified original articles, recent reviews [8], chapters from texts
[9,10], and recent treatment guidelines [1,11,12].
Study Selection
In selected studies, all patients had bacteriologically confirmed
(by smear and/or culture) active pulmonary TB, and reported
treatment outcomes of bacteriologically confirmed failure and/or
relapse. Treatment was standardized and included at least rifampin.
We excluded studies or arms that utilized rifapentine, rifabutin, or
nondrug therapy (for example, immunotherapeutic vaccines). We
also excluded regimens with once weekly or single drug therapy, as
these would now be considered inadequate [11–13].
The selection of articles for review was done independently by
two investigators in three stages: titles alone, then abstracts, and
then full text articles. Decisions were compared and disagreements
about study selection were resolved by consensus or by involving a
third reviewer. We initially planned to select only RCTs in
previously treated patients. We could not identify any randomized
trial that evaluated specifically the current WHO retreatment
regimen (2SHRZE/1HRZE/5HRE). Therefore, we included any
cohort studies that used this specific regimen, reported individual
outcomes, and met all inclusion criteria above.
We found only 11 randomized trials in previously treated
patients, of which nine evaluated patients with isoniazid mono-
resistance (these trials used several different regimens, but all
different from the WHO retreatment regimen). Therefore, we
decided to include trials, identified in a separate systematic review,
in which previously untreated patients with mono-resistance to
isoniazid were treated with standardized rifampin containing
regimens. (For methods, see Menzies et al. [14].)
Data Extraction and Quality Assessment
We used standardized forms to extract data from selected
studies about patient population and characteristics, treatment
regimen, and pretreatment drug-susceptibility testing—if done,
supervision of treatment, funding source, and number of patients
who started treatment, died, failed, relapsed, defaulted, or were
otherwise lost. Two reviewers extracted the data, with disagree-
ments resolved by consensus.
The selection criteria requiring microbiologic confirmation of
initial diagnosis and treatment outcomes meant that selected
studies had high-quality diagnostic methods. Another indicator of
study quality was the number of patients who refused therapy,
dropped out, moved away, or were otherwise unaccounted for
during therapy. Trials were considered to have high-quality
methods of randomization if they used central randomization,
numbered opaque sealed envelopes, sealed envelopes from a
closed bag, or numbered or coded bottles or containers.
Outcomes
Treatment failure was defined as sputum smears and/or
cultures that were consistently positive or positive requiring
treatment after at least 5 mo of therapy [15]. Relapse was defined
as recurrence of positive smears and/or cultures that required
therapy 1 mo or more after apparent cure [15]. Acquired drug
resistance was defined as new or additional resistance to one or
more of the TB drugs received—in the setting of failure or relapse.
Patients with pretreatment rifampin resistance, including multi-
drug resistance, were excluded from analysis, if identified in the
published report.
Data Synthesis and Analysis
We were interested to understand the efficacy of different
regimens in preventing failure, relapse, and acquired drug
resistance—end-points with objective microbiological definitions
that were consistent across trials. Therefore, we used a per-
protocol analysis, excluding patients who did not complete therapy
because they developed serious adverse reactions, died, defaulted,
dropped out, or were otherwise not accounted for.
Only 6 cohort studies were found that evaluated the current
WHO retreatment regimen; these results were not pooled. Of 11
trials in previously treated patients, nine included patients with
mono-resistance to isoniazid, one included patients only with poly-
drug resistant strains [16], while another, which included patients
with multiple forms of resistance, did not report results by type of
drug resistance [17]. Results from the last two trials were not
analyzed. To increase power, results from the nine trials in
isoniazid mono-resistant previously treated patients were pooled
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resistance in 24 trials in new cases.
Very few trials with head-to-head comparisons were identified,
and no two trials made the same comparisons. Hence we pooled
results across all trials, effectively treating each arm within each
trial as an independent cohort. For this across-trial analysis, we
used a random effects meta-analysis to estimate the overall pooled
estimates of cumulative incidence and 95% CI of failure, relapse,
and acquired drug resistance using PROC NLMIXED in SAS
(SAS institute, Carey, NC, USA) [18]. We used the exact binomial
likelihood approach [18], which uses a binomial distribution to
approximate the distribution of the outcome of interest. This
approach accounts for study size and includes a random effect to
account for inter-study heterogeneity. When proportions are the
outcome measure, this approach has been demonstrated to
produce less-biased estimates of the pooled effect and the
between-study variability [18]. To minimize heterogeneity, we
performed subgroup analyses stratified by predefined covariates
of interest. These included the following characteristics of the
re-treatment regimen duration and dosing schedule of rifampin,
initial drug resistance, use of pyrazinamide or streptomycin, and
number of drugs to which the organism was susceptible used in the
initial or continuation phase (the initial intensive phase was
defined as the initial period when more drugs were used—usually
the first 1–2 mo—while the continuation phase was the remainder
of therapy). We also examined the effect of supervision of therapy,
proportion that were smear positive, and default or other losses
during treatment phase follow-up. We assessed heterogeneity of
outcomes of interest, within subgroups defined by covariates of
interest by estimating the I
2 statistic and associated 95% CIs [19].
Finally, meta-regression was used to estimate the effect of the
treatment factors of interest, after adjustment for other potentially
confounding patient and treatment covariates. Because the
outcomes we were pooling were proportions, rather than odds
ratios, and because these proportions were usually small, we
performed meta-regression using the Poisson model [20] that
allowed for overdispersion (i.e., negative binomial regression). In
this meta-regression, each arm in each study was the unit of
analysis, cumulative incidence of TB treatment outcomes was the
dependent variable, and TB treatment characteristics were the
independent variables. An offset was used to account for size of
study. In this approach, residual heterogeneity between studies is
accounted for in the dispersion parameter. As such, we interpreted
the dispersion parameter as indicating there was no remaining
unexplained heterogeneity if the value was not significantly
different from 0, and as minimal heterogeneity if the value was
less than 1.0 [21]. Effect estimates of the meta-regression model
were interpreted as adjusted incidence rate ratios [20]. We tested
the significance of each factor in the models using the likelihood
ratio test.
The final model included rifampin duration, intermittent
schedule, use of pyrazinamide and streptomycin, number of drugs
in initial or continuation phases to which organisms were
susceptible, length of follow-up after end of treatment (for relapse
and acquired drug resistance), supervision of therapy (directly
observed therapy [DOT]), and noncompletion of therapy because
of protocol violations, patient refusal, default, moved, or lost.
Results
Study Selection
As seen in Figure 1, 1,464 citations were identified from the
search of the three electronic databases. Of these, 147 were
retained for abstract review and 96 for full text review. In total,
six cohort studies were found describing results with the stan-
dardized 8-mo retreatment in previously treated patients with
pretreatment drug susceptibility testing (DST) [6,22–26], and 12
reports describing nine randomized trials in previously treated
patients with isoniazid mono-resistance [27–38]. To these, we
added results in previously untreated patients with initial mono-
resistance to isoniazid taken from 38 published reports describing
24 randomized trials [39–75]. The initial diagnosis and outcomes
were confirmed with cultures (i.e., not just smears) in all
randomized trials. In the trials, rifampin dose was 600 mg (or
10–12 mg/kg) in all trials except three trials that used 450 mg
daily [29,33,67], one that used 450 mg daily followed by 600 mg
thrice weekly [34], and one with 450 mg daily followed by 900 mg
twice weekly [31]. Other characteristics of the studies and study
populations are summarized in Table S1.
Results from Cohort Studies with Standardized WHO
Retreatment Regimen
As shown in Table 1, failure rates were low in most cohorts with
pan-sensitive strains that received the standardized retreatment
regimen, although the rate was inexplicably high in one study [25].
In cohorts with mono-resistance to isoniazid, failure rates ranged
from 18%–44%, compared to 9%–45% in cohorts whose drug
resistance patterns were not reported. Pooled estimates were not
calculated because of heterogeneity in results.
Results from RCTs in Previously Treated Patients with INH
Mono-resistance
In the nine randomized trials, summarized in Table 2,
randomization was high quality in eight, and treatment phase
losses were less than 10% in six. Regimens and treatment
outcomes varied widely. In three studies that used the standard
therapy for drug-sensitive TB of 2HRZ (6E)/4HR [28,29,32], the
combined failure and relapse rates ranged from 29%–70%. In four
studies [30,31,34–38] in which patients were given rifampin plus
ethambutol for 12 mo or more, failure rates ranged from 4%–23%
and relapse rates from 0%–27%. The regimen most like the
current retreatment regimen was evaluated in a single trial [27]. A
total of 179 evaluable patients received 2SRZE/4RE or 2SRZE/
7RE with failure and relapse rates of 1% and 3%, respectively
[27]. In one arm of one trial, among 89 patients who received a
similar regimen of 3REZ/9RE (albeit thrice weekly), failure and
relapse rates were 23% and 20%, respectively [34].
Pooled Results for Isoniazid Mono-resistance from All
Trials
In the 24 randomized trials in new cases, randomization was
high quality in 16, but not specified in eight, and treatment phase
losses were less than 10% in 18 (67%). In the total of 33 trials with
patients with isoniazid mono-resistance, treatment failure was
assessed in 1,907 patients within 101 different treatment arms,
relapse in 1,196 persons in 93 arms, and acquired drug resistance
was assessed in 1,484 patients in 76 different arms. As seen in
Table 3, failure was significantly lower if streptomycin was used, or
if a larger number of effective drugs were used in the initial or
continuation phases. Failure rates progressively fell with longer use
of pyrazinamide, although all CIs overlapped. There was also a
trend for higher failure rates if rifampin was used for only 2 mo, or
drugs were administered biweekly throughout therapy. Results
were very similar when the analysis was restricted to high-quality
studies—in which less than 10% of participants dropped out,
moved, or were otherwise lost to follow-up during the treatment
phase.
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randomized trials of patients with INH resistance, compared to
15% in the subgroup with INH resistance in randomized trials of
new cases (Figure S1B), with substantial variation in rates in
different studies. As shown in Table 4, relapse rates were
significantly higher if rifampin was used for only 2 mo. Nonsignif-
icant but potentially important differences in relapse rates were seen
with biweekly dosing schedules in the initial intensive phase, and
with fewer effective drugs in the initial intensive phase. As shown in
Table 5, acquired drug resistance (i.e., amplification of drug
resistance) was significantly lower with use of streptomycin or a
greater number of effective drugs in the initial intensive phase. As
with failure, acquired drug resistance was progressively less frequent
with longer use of pyrazinamide, although all CIs overlapped.
Death during treatment was not analyzed as a primary outcome
because most studies did not report the timing of death, and early or
late deaths during treatment may have very different risk factors.
Mortality during treatment was higher in patients treated with
regimens for 1 y or longer (unpublished data). After accounting for
this, death during treatment was not associated with any other
treatment characteristic (unpublished data).
Meta-regression Results
In meta-regression (Table 6), patients with pretreatment
isoniazid resistance had significantly worse treatment outcomes if
therapy was intermittent (two or three times weekly) or included
fewer effective drugs—in the initial intensive phase. Relapse was
lower with longer duration of rifampin or pyrazinamide, but was
not associated with duration of post-treatment follow-up. The 95%
CI for the dispersion estimates for all three final models included 1,
suggesting that the treatment factors included in these models
accounted for the majority of the heterogeneity in outcomes seen.
Discussion
The most striking finding of this review is the remarkable lack of
evidence in support of the WHO recommended retreatment
regimen currently used to treat as many as one million TB patients
every year [2]. The current body of evidence for treatment of
previously treated patients is a dog’s breakfast—a few cohort
studies in patients with pretreatment drug sensitivity testing, a
limited number of randomized trials in previously treated patients,
and many small subgroups with initial drug resistance included in
trials of new cases. Yet these are the only available results, and so
must be extrapolated, albeit very cautiously, to the enormous
challenge in resource-limited settings of treating the large number
of patients, with a wide spectrum of drug resistance, who require
retreatment.
This review is a reminder that, unlike the current initial
treatment regimens, the current retreatment regimen was not
tested and refined in a sequence of randomized trials. Instead, this
regimen was the product of expert opinion [3]. Importantly, this
was designed for settings with low prevalence of initial drug
resistance and patients who had been treated with a regimen that
included rifampin only for the first 2 mo [3]. In this situation, the
regimen has high success rates [76]. But treatment outcomes are
much worse when used in settings with high initial drug resistance,
for patients who previously received regimens with rifampin
throughout [2,6,77].
The most important limitation of the review is also the most
striking finding—the absence of published trials evaluating the
current retreatment regimen and the remarkably small number of
trials evaluating treatment in previously treated patients. None of
these trials included HIV co-infected patients—limiting applica-
bility of the findings to this important population. Because trials
compared very different treatment regimens, we could not pool
Table 1. Cohort studies reporting results with standardized retreatment regimen recommended by WHO.
ID Reference Regimen
a
Total Number
Treated
Number at Risk
for Failure
b
Number (%)
Who Failed
Number at Risk for Acquired
Drug Resistance
c
Number with Acquired
Drug Resistance
Pan-sensitive strains
33 [22] 2HRZES/1HRZE/5HRE 382 306 2 (0.7%) 306 1
34 [23] 2HRZES/1HRZE/5HRE 30 28 0 28 0
340 [25] 2HRZES/1HRZE/5HRE 122 87 5 (6%) — —
2HRZES/1HRZE/5[HRE]2 260 208 13 (6%) — —
2HRZES/1HRZE/5[HRE]3 104 64 17 (27%) — —
Mono-resistance to INH
340 [25] 2HRZES/1HRZE/5HRE 57 39 7 (18%) — —
2HRZES/1HRZE/5[HRE]2 37 31 6 (19%) — —
2HRZES/1HRZE/5[HRE]3 30 18 8 (44%) — —
Mixed drug resistance (all forms or unknown)
324 [24] 2[HRZES]3/1[HRZE]3/5[HRE]3 57 46 4 (9%) — —
2[HRZES]3/2[HRZE]3/5[HRE]3 17 11 5 45%) — —
384 [6] 2HRZES/1HRZE/5EHR 210 183 47 (26%) — —
415 [26] 2[HRZES]3/1[HRZE]3/5[HRE]3 507 389 52 (13%) — —
None of these studies ascertained relapse after treatment completion.
aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin. Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters
to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of
continuation phase treatment. [ ] indicate intermittent therapy; subscript number after [ ] indicates number of doses per week.
bNumber at risk for failure excluded those who died, defaulted, or had serious adverse reactions during therapy (i.e., included only those who completed treatment or
failed).
cIf acquired drug resistance was not measured, this is indicated as ‘‘—’’.
doi:10.1371/journal.pmed.1000150.t001
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potential confounding. For example, virtually all intermittent
therapy was wholly supervised; if intermittent therapy in the initial
phase was inferior, this would make supervised therapy appear
worse in stratified analysis. The across-trial analysis is also more
questionable when outcomes are very heterogeneous. For
example, failure and relapse rates differed considerably between
the four trials, which evaluated apparently similar regimens of at
least 12 mo of rifampin plus ethambutol [30,31,34–38]. This may
reflect the heterogeneity of study populations and settings, as
studies were conducted in low-, middle-, and high-income
countries over a span of almost 30 years. We attempted to reduce
this heterogeneity by performing stratified analysis for major
covariates, and by restricting the pooled analysis to patients with
confirmed isoniazid mono-resistant pulmonary TB. We also used a
more conservative meta-analytic method for pooled estimates and
95% CIs [18]. Concerns over the heterogeneity from the variety of
settings and populations are alleviated somewhat by the consis-
tency of results observed in the stratified analysis and the meta-
regression. This consistency provides greater confidence in the
most important associations found.
A primary objective of this review was to compare the efficacy
of different treatment regimens for INH mono-resistance. To
accomplish this, we have analyzed the per-protocol results from
Table 2. Regimens and results in randomized trials in previously treated patients with INH mono-resistance.
ID Reference Regimen
a
Total
Number
Treated
At Risk for
Failure (N)
b
Number (%)
who Failed
At Risk for
Relapse (N)
c
Number (%)
who Relapsed
At Risk for
Acquired Drug
Resistance (N)
b
Number (%)
with Acquired
Drug Resistance
14 [27] 2SZRE/4RE 101 91 0 72 3 (4%) 91 0
2SZRE/7RE 97 88 1 (1%) 72 2 (3%) 88 0
23 [28] 2[HRZE]3/4[HR]2 171 167 32 (19%) 135 14 (10%) 167 23 (14%)
50 [29] 2HRZE/6EH 101 94 16 (17%) 73 6 (8%) 94 3 (3%)
2[HRZE]2/4[HRE]2 63 59 12 (20%) 44 11 (25%) 59 7 (12%)
2[HRZ]2/4[HR]2 79 74 46 (62%) 27 4 (15%) 74 13 (18%)
302 [34] Subgroup with isoniazid
mono-resistance
12RE (RIF 450) 83 73 20 (27%) 19 5 (26%) 73 19 (26%)
12[RE]3 (RIF 450) 91 75 22 (29%) 22 6 (27%) 75 21 (28%)
3[REZ]3/9[RE]3 (RIF 450) 89 77 18 (23%) 30 6 (20%) 77 17 (22%)
3[RE]3/9[RE]3 (RIF 450) 94 75 10 (13%) 35 12 (34%) 75 10 (13%)
302 [34] Subgroup with isoniazid
and ethambutol resistance
12RE (RIF 450) 25 15 10 (67%) 5 1 (20%) — —
12[RE]3 (RIF 450) 22 12 8 (67%) 4 1 (25%) — —
3[REZ]3/9[RE]3 (RIF 450) 20 12 5 (42%) 7 0 — —
3[REPt]3/9[RE]3 (RIF 450) 16 6 2 (33%) 4 1 (25%) — —
326 [31] 12ER (RIF 450) 112 106 11 (10%) — — 106 9 (8%)
12[ER]2 (RIF 450) 93 87 16 (18%) — — 87 15 (17%)
328 [32] 2HRZ/4HR 9 9 3 (33%) 6 1 (17%) 6 0
2HRZ/4(HR)2 44 1 ( 2 5 % ) 3 0 3 0
357 [33] 6HRZ 9 9 0 — — — —
6HRE 10 10 5 (50%) — — — —
6HRZ 15 9 0 — — — —
6HRE 15 10 5 (50%) — — — —
400 [30,35,36,38] 3RE/9[RE]2 43 40 2 (5%) 38 2 (5%) — —
3RE/9[RE]2 (RIF 1200) 42 39 2 (5%) 37 0 — —
3RE/15[RE]2 (RIF 1200) 43 40 1 (3%) 40 2 (5%) — —
3RE/21[RE]2 (RIF 1200) 42 39 1 (3%) 38 0 — —
416 [37] 1.5RE/10.5[RE]3 34 30 2 (7%) 23 0 — —
12[RE]3 38 33 4 (12%) 25 0 — —
Dose of rifampin=600 mg daily unless indicated otherwise.
aRegimen abbreviations: H, isoniazid; R, rifampin; Z, pyrazinamide; E, ethambutol; S, streptomycin. Letters to left of ‘‘/’’ indicate regimen in initial intensive phase; letters
to right of ‘‘/’’ indicate regimen in continuation phase. First number signifies the months of initial phase of treatment and the second number signifies the months of
continuation phase treatment. [ ] indicate intermittent therapy; subscript number after [ ] indicates number of doses per week.
bNumber at risk for failure, relapse, or acquired drug resistance excluded those who died, defaulted, or had serious adverse reactions during therapy (i.e., included only
those who completed treatment or failed).
cIf relapse or acquired drug resistance not measured, it is indicated as ‘‘—’’.
doi:10.1371/journal.pmed.1000150.t002
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studies reviewed reported adverse events, dropouts, and defaulters
separately, facilitating our approach. However, we did not include
these outcomes because their definitions and ascertainment were
not well standardized, potentially creating greater between-study
variability. As well, differences between studies in providers and
populations might have had greater influence on these outcomes
than the differences in treatment response, potentially creating
substantial bias with our analytic approach. Excluding patients
who dropped out or defaulted would tend to underestimate
treatment effects if these outcomes had been associated with the
same treatment characteristics as failure or relapse. However,
when this was examined, we found that the proportion that
completed therapy was not significantly associated with any of the
important treatment characteristics.
We did not study the effect of rifampin dose—largely most
studies used the same dose (10–12 mg/kg), limiting power to
detected associations of outcomes with dose. However some
studies used 450 mg daily, at least initially, which may have been
inadequate and contributed to the poor outcomes seen, leaving the
optimal dose of rifampin still unresolved. We also could not
distinguish between relapse of the same strain of Mycobacterium
tuberculosis causing the initial infection versus re-infection with a
new strain of the bacillus. In settings with high rates of ongoing
exposure to M. tuberculosis, particularly if HIV seroprevalence is
also high, a relatively high proportion of cases of recurrent TB
Table 3. Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or
previously treated cases: Failure in isoniazid mono-resistance.
Factor Arms (N) Events/Patients (N) Pooled Event Rate 95% CI I
2 (95% CI)
Rifampin use
Rifampin 1–2 mo 19 30/256 6.2 0–12.8 0 (0–0.48)
Rifampin 3–5 mo 10 2/88 0.9 0–2.9 0 (0–0.60)
Rifampin 6–7 mo 46 108/645 4.8 0.8–8.8 0.76 (0.69–0.82)
Rifampin 8+ mo 19 136/858 7.4 0–15.1 0.87 (0.82–0.91)
Frequency of therapy in the initial intensive phase
a
Daily 65 99/1,062 5.1 2.2–8.0 0.50 (0.33–0.62)
Thrice weekly 25 102/559 5.2 0–10.5 0.44 (0.10–0.65)
Twice weekly 4 75/226 25.5 0–52.8 0.93 (0.86–0.97)
Duration of PZA
No PZA 28 123/769 11.4 4.0–18.8 0.74 (0.63, 0.82)
1–3 mo 39 147/871 6.6 2.3–10.9 0.83 (0.77–0.87)
4 mo or more 27 6/207 1.7 0–3.6 0 (0–0.42)
Duration of streptomycin
No streptomycin 43 258/1,294 13.6 7.8–19.3 0.80 (0.73–0.85)
1–3 mo 28 13/383 2.8 0.6–5.0 0 (0–0.41)
4 mo or more 23 5/170 2.1 0–4.5 0 (0–0.46)
Number of drugs to which strains susceptible (effective drugs)
Initial phase
b
1 drugs 3 22/39 50.8 6.1–9.6 0.52 (0–0.86)
2 drugs 31 99/628 11.3 0.3–19 0.58 (0.37–0.72)
3 drugs 55 148/932 3.8 0.9–6.7 0.58 (0.43–0.69)
4 or more drugs 3 1/185 0.4 0–1.5 0 (0–0.73)
Continuation phase
0–1 drugs 44 153/688 9.1 3.0–15.2 0.71 (0.61–0.79)
2 drugs 35 116/998 6.0 1.6–10.5 0.72 (0.61–0.80)
3 or more drugs 11 1/92 0.5 0–1.6 0 (0–0.58)
Supervision of therapy
All doses fully supervised 69 148/1,341 3.8 1.2–6.3 0.59 (0.46–0.68)
None/partial supervision 25 128/506 13.8 4.7–22.8 0.80 (0.71–0.86)
Completion of treatment
$90% 55 187/1,353 6.0 2.0–9.9 0.78 (0.71–0.83)
,90% 39 89/494 6.5 0.7–12.4 0.50 (0.28–0.66)
Event rate and 95% CI are in bold if CIs for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given
daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.
bIn a few trials, the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000150.t003
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However, very few patients had HIV co-infection in the studies
reviewed, and in studies with longer follow-up, the great majority
of relapses occurred in the first 1–2 y, with very few occurring in
the third to fifth years. This suggests re-infection should have
accounted for very few of the disease recurrences. Only four
studies with 95 patients had less than 1 y follow-up; overall relapse
rate in these studies was 10.5%, compared to 11.7% in all studies.
Unequal follow-up should not have affected results, since duration
of post-treatment follow-up was not associated with relapse or
acquired drug resistance in multivariable analysis.
We restricted the research to three languages and three
databases, raising the issue of adequacy of our search—germane
since we found little evidence and no randomized trials assessing
the current WHO regimen. A recent study found that 84% of
published papers on TB were published in English, French, and
Spanish [79]. Nevertheless, we may have missed some studies
because of the language restriction or the database restriction.
However, when these findings were presented to expert groups at
WHO, the International Union against Tuberculosis and Lung
Disease, the Pan American Health Organization, and the
American Thoracic Society, no additional relevant studies were
identified by those attending. While somewhat reassuring, this
cannot be considered systematic, nor evidence.
Given that 10%–20% of all patients receiving TB treatment in
low- and middle-income countries require retreatment [2], it is
Table 4. Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or
previously treated cases: Relapse in isoniazid mono-resistance.
Factor Arms (N) Events/Patients (N) Pooled Event Rate (95% CI) I
2 (95% CI)
Rifampin use
Rifampin 1–2 mo 18 43/196 23.8 11.6–36.0 0.44 (0.02–0.68)
Rifampin 3–5 mo 10 10/83 9.2 0.9–17.5 0 (0–0.60)
Rifampin 6–7 mo 43 46/479 7.1 3.4–10.9 0 (0–0.35)
Rifampin 8+ mo 17 38/409 4.6 0.6–8.6 0.58 (0.29–0.76)
Frequency of therapy in the initial intensive phase
a
Daily throughout 60 76/738 9.3 5.2–13.5 0.25 (0–0.47)
Thrice weekly throughout 25 46/353 7.3 1.5–13.1 0.07 (0–0.39)
Twice weekly throughout 3 15/76 13.4 0–33.3 0 (0–0.73)
Duration of PZA
No PZA 25 45/365 10.9 3.6–18.2 0.53 (0.26–0.70)
1–3 mo 38 78/641 10.1 5.1–15.2 0.28 (0–0.53)
4 mo or more 25 14/161 6.4 1.4–11.3 0 (0–0.43)
Duration of streptomycin
No streptomycin 38 77/705 7.5 3.3–11.7 0.41 (0.13–0.60)
1–3 mo 28 46/328 13.2 6.4–20.0 0.43 (0.11–0.64)
4 mo or more 22 14/134 6.9 1.1–12.8 0 (0–0.45)
Number of drugs to which strains susceptible (effective drugs)
Initial phase
b
1 drugs 3 3/17 15.3 0–40.8 0 (0–0.73)
2 drugs 26 24/278 7.7 1.2–14.1 0.11 (0–0.44)
3 drugs 54 105/675 12.2 6.2–18.2 0 (0–0.32)
4 or more drugs 3 5/149 2.6 0–7.9 0 (0–0.73)
Continuation phase
0–1 drugs 43 71/514 9.3 4.0–14.5 0 (0–0.35)
2 drugs 30 55/516 11.1 4.2–17.9 0.52 (0.28–0.69)
3 or more drugs 11 10/83 8.0 0–16.7 0 (0–0.58)
Supervision of therapy
All doses fully supervised 66 107/861 12.3 7.7–16.8 0.36 (0.14–0.53)
None or partial supervision 22 30/306 5.8 1.6–10.0 0 (0–0.46)
Completion of treatment
$90% 51 97/886 11.1 6.5–15.7 0.40 (0.16–0.57)
,90% 37 40/281 8.2 3.1–13.3 0 (0–0.37)
Event rate and 95% CI are in bold if CIs for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given
daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.
bIn a few trials, the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000150.t004
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strategy. Results with the current WHO retreatment regimen in
the cohorts with pretreatment isoniazid resistance or mixed/
unknown resistance were disturbingly poor. This may reflect
inaccuracies in the performance of the drug sensitivity testing in
these earlier studies, although high failure rates [2] and
amplification of drug resistance have been documented under
programme conditions [4,77]—supporting our findings. Hence,
the most immediate needs identified by this review are to enhance
access to accurate drug sensitivity testing for isoniazid and
rifampin, and to redesign the recommended standardized
retreatment regimen. This redesign should assume that rifampin
will have been used throughout initial therapy and follow
principles suggested by this review’s pooled analysis for isoniazid
mono-resistance. Intermittent therapy should be avoided in the
initial intensive phase of the re-treatment regimen, at least four
effective drugs should be used initially, and at least three effective
drugs in the continuation phase. This review also provides support
for prolonged use of pyrazinamide and use of streptomycin initially
(or an alternative injectable drug in settings with high streptomycin
resistance).
The long-term implication of this review is the dire need for
evidence-based treatment of patients with drug resistance of all
forms—in line with a recent call for research in drug resistant TB
[80]. Among new cases, the global weighted mean prevalence of
multi-drug resistant TB is 2.9%, but 14.1% have other forms of
Table 5. Stratified analysis of covariates associated with TB treatment outcomes in RCT of patients with INH resistance in new or
previously treated cases: Acquired drug resistance in isoniazid mono-resistance.
Factor Arms (N) Events/Patients (N) Pooled Event Rate (95% CI) I
2 (95% CI)
Rifampin use
Rifampin 1–2 mo 17 6/222 1.9 0–4.3 0 (0–0.50)
Rifampin 3–5 mo 8 2/67 2.0 0–5.8 0 (0–0.65)
Rifampin 6–7 mo 39 51/580 3.6 0.4–6.8 0.33 (0.01–0.55)
Rifampin 8+ mo 9 92/592 7.4 0–15.7 0.91 (0.86–0.95)
Frequency of therapy in the initial intensive phase
a
Daily throughout 48 41/739 2.8 0.7–4.9 0 (0–0.41)
Thrice weekly throughout 21 74/496 5.1 0–10.5 0 (0–0.46)
Twice weekly throughout 4 36/226 15.5 0–33.4 0 (0–0.77)
Duration of PZA
No PZA 14 76/473 10.0 1.2–18.8 0 (0–0.71)
1–3 mo 36 71/836 3.7 0.8–6.6 0.55 (0.34–0.69)
4 mo or more 23 4/152 1.2 0–3.1 0 (0–0.45)
Duration of streptomycin
No streptomycin 26 143/963 12.5 7.6–17.3 0.55 (0.30–0.71)
1–3 mo 25 6/347 1.7 0.2–3.3 0 (0–0.43)
4 mo or more 22 2/151 1.1 0–2.8 0 (0–0.45)
Number of drugs to which strains susceptible (effective drugs)
Initial phase
b
0–1 drugs 0 0 — — —
2 drugs 21 72/415 12.0 4.0–20.0 0 (0–0.45)
3 drugs 49 79/861 3.8 1.0–6.6 0 (0–0.33)
4 or more drugs 3 0/185 0 0–1.4 0 (0–0.73)
Continuation phase
0–1 drugs 35 56/589 4.5 0.8–8.2 0 (0–0.38)
2 drugs 27 94/790 4.9 0.5–9.2 0.76 (0.65–0.83)
3 or more drugs 9 1/76 0.6 0–2.2 0 (0–0.62)
Supervision of therapy
All doses fully supervised 57 103/1,089 3.1 0.7–5.5 0.51 (0.34–0.64)
None or partial supervision 16 48/372 7.8 0.7–15.0 0.48 (0.07–0.71)
Completion of treatment
$90% 42 96/1,071 3.4 0.6–6.2 0.6 (0.4–0.8)
,90% 31 55/390 5.0 0.3–9.7 0 (0–0.40)
Event rate and 95% CI are in bold if CIs for two or more strata do not overlap.
aIn all but one trial, if therapy was intermittent initially the same schedule was continued throughout therapy. In trials where therapy was daily initially, it was given
daily, thrice, or twice weekly thereafter, but outcomes were not different, so these regimens were considered equivalent.
bIn a few trials, the number of drugs was the same throughout—these were classified according to the starting regimen.
doi:10.1371/journal.pmed.1000150.t005
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[81]. The need for trials in MDR TB [82] is inarguable. Although
perhaps lacking the cachet of MDR, treatment of these other
forms of drug resistance in new cases must also be given priority,
for several reasons. First, these other forms of drug resistance are
almost five times more common than MDR [81], accounting for
1.3 million new cases in 2008 (extrapolating from the estimated
number of 9.2 million new cases [83]. In view of evidence that use
of INH preventive therapy may result in increasing levels of INH
resistance [84,85], isoniazid resistance may further increase in
countries responding to the ‘‘3 I’s’’ initiative of WHO for
prevention of HIV-TB [86]. Second, this review has demonstrated
the profound weakness of the evidence base for treatment of most
forms of drug resistance, including isoniazid resistance. Third,
there is good evidence (see [14]) that isoniazid and streptomycin
resistance (each alone, or together) result in substantially worse
treatment outcomes. Finally, this review and observational studies
demonstrate that inadequate re-treatment regimens can result in
high rates of failure and relapse with amplified drug resistance.
Hence an effective regimen for the group that requires re-
treatment could reduce generation of MDR.
A number of priorities for research can be identified from the
findings of this review. These include the need for tailoring
different regimens for various forms of resistance, the establish-
ment of the minimum number of effective drugs used in the initial
or continuation phases (to be balanced against tolerability and
costs), the optimal dose of rifampin, the use and timing of
intermittent administration, and use and duration of pyrazinamide
or an injectable drug (including the utility of streptomycin in
settings with high prevalence of streptomycin resistance). There is
no doubt that such trials will be challenging, and large numbers of
patients will be required. Hence multicenter and multinational
Table 6. Adjusted incidence rate ratios of failure, relapse, and acquired drug resistance in INH resistant strains.
Factor Failure Relapse Acquired Drug Resistance
a
Duration of rifampin therapy
1–2 mo 4.1 (1.2–13.4) 3.8 (1.6–9.0) 0.7 (0.4–1.3)
3–4 mo 0.8 (0.2–5.0) 1.9 (0.7–5.2) 1.0 (0.3–3.0)
5–7 mo 1.0 (reference) 1.0 (reference) 1.0 (reference)
$8 mo 1.6 (0.8–2.8) 1.0 (0.5–2.0) 2.1 (0.9–4.9)
Overall significance (p-value)
b (0.004) (0.02) (0.20)
Number of drugs in regimen to which strains sensitive
Initial intensive phase
0 or 1 drug 6.9 (1.4–33) 5.9 (1.0–33) No obs.
2 drugs 2.7 (0.7–10.0) 1.9 (0.6–6.7) 18 (1.4–99)
3 drugs 1.6 (0.4–6.0) 3.1 (0.9–9.9) 9.6 (0.8–99)
4 or more drugs 1.0 (reference) 1.0 (reference) 1.0 (reference)
Overall significance (p-value)
b (0.06) (0.12) (0.25)
Continuation phase
0 or 1 drug 2.5 (0.7–9.0) 1.0 (0.5–2.3) 1.8 (0.5–6.5)
2 drugs 2.2 (0.6–8.5) 1.2 (0.7–2.5) 1.2 (0.3–5.0)
3 or more drugs 1.0 (reference) 1.0 (reference) 1.0 (reference)
Overall significance (p-value)
b (0.36) (0.80) (0.25)
Frequency of therapy
Initial daily 1.0 (reference) 1.0 (reference) 1.0 (reference)
Thrice weekly throughout 3.6 (1.6–7.7) 2.1 (1.0–4.9) 2.1 (0.9–4.5)
Twice weekly throughout 3.3 (1.8–6.2) 5.8 (1.8–18. 2) 1.6 (1.1–2.3)
Overall significance (p-value)
b (0.0003) (0.01) (0.14)
Streptomycin
Not used 1.0 (reference) 1.0 (reference) 1.0 (reference)
Used (2 wk or more) 0.4 (0.2–0.9) 1.1 (0.5–2.2) 0.5 (0.2–1.0)
Overall significance (p-value)
b (0.007) (0.80) (0.003)
Pyrazinamide
Not used 1.0 (reference) 1.0 (reference) 1.0 (reference)
Used (2 wk or more) 1.2 (0.6–2.0) 0.5 (0.2–1.0) 1.5 (0.9–2.3)
Overall significance (p-value)
b (0.52) (0.05) (0.15)
IRR, incidence rate ratios, from negative binomial regression. The percentage completing treatment, mean age, mean percentage male, mean percentage smear
positive, and duration of post-treatment follow-up were not significantly associated with any of the three outcomes in preliminary models, so they were dropped from
the final model. Incidence rate ratios and 95% CI are in bold if significantly different from reference group.
aAcquired drug resistance in failures and/or relapses combined.
bSignificance of each factor in multivariate model from log likelihood ratio test.
doi:10.1371/journal.pmed.1000150.t006
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scientific direction, and funding at an international level [80]. The
potential availability of new drugs in the near future increases the
need for adequate trials to avoid misuse of these new agents.
Conclusions
We conclude that there is little published evidence to support
the continued use of the currently recommended retreatment
regimen. There is an urgent need for a concerted international
effort to substantially expand access to reliable drug sensitivity
testing and to initiate randomized trials in patients with
pretreatment drug resistance of all forms, particularly in previously
treated patients. While awaiting results of these trials, the
standardized retreatment regimen should be redesigned—at
minimum to adequately treat patients with isoniazid resistance.
In fact, the upcoming revised treatment guidelines from the WHO
will consider these issues and provide some guidance on how to
manage previously treated patients [87].
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Background. Every year, nearly ten million people develop
tuberculosis—a contagious infection, usually of the lungs—
and about 2 million people die from the disease.
Tuberculosis is caused by Mycobacterium tuberculosis,
bacteria that are spread in airborne droplets when people
with the disease cough or sneeze. Its symptoms include a
persistent cough, fever, weight loss, and night sweats.
Diagnostic tests for tuberculosis include chest X-rays and
sputum slide exams and cultures in which bacteriologists try
to grow M. tuberculosis from mucus brought up from the
lungs by coughing. The disease can be cured by taking
several powerful antibiotics regularly (daily or several times a
week) for at least 6 months. However, 10%–20% of patients
treated for tuberculosis in low- and middle-income countries
need re-treatment because the initial treatment fails to clear
M. tuberculosis from their body or because their disease
returns after they have apparently been cured (treatment
relapse). Patients who need re-treatment are often infected
with bacteria that are resistant to one or more of the
antibiotics commonly used to treat tuberculosis.
Why Was This Study Done? As part of its strategy to
reduce the global burden of tuberculosis, the World Health
Organization (WHO) recommends standardized treatment
regimens for tuberculosis. For re-treatment, WHO
recommends an 8-month course of isoniazid, rifampin, and
ethambutol with pyrazinamide and streptomycin added for
the first 3 and 2 months, respectively. All these drugs are
given daily (the preferred regimen) or three times a week.
Unfortunately, although this regimen is now used to treat
about 1 million patients each year, it yields poor results,
particularly in regions where drug resistance is common. In
this study (which was commissioned by WHO to provide the
evidence needed for a revision of its treatment guidelines),
the researchers undertake a systematic review (a search
using specific criteria to identify relevant research studies,
which are then appraised) and a meta-analysis (a statistical
approach that pools the results of several studies) of
randomized trials and cohort studies (two types of study
that investigate the efficacy of medical interventions) of re-
treatment regimens in previously treated tuberculosis
patients, and in patients with infection that was resistant
to isoniazid (‘‘mono-resistance’’).
What Did the Researchers Do and Find? The
researchers’ systematic search for published reports of
randomized trials and cohort studies of the currently
recommended re-treatment regimen identified no relevant
randomized trials and only six cohort studies. In the three
cohort studies in which the participants carried M.
tuberculosis strains that were sensitive to all the antibiotics
in the regimen, failure rates were generally low. However, in
the studies in which the participants carried drug-resistant
bacteria, failure rates ranged from 9% to 45%. The
researchers also identified and analyzed the results of nine
trials in which several re-treatment regimens, all of which
deviated from the standardized regimen, were used in
previously treated patients with isoniazid mono-resistance.
In these trials, the combined failure and relapse rates ranged
from 0% to more than 75%. Finally, the researchers analyzed
the pooled results of 33 trials that investigated the effect of
various regimens on nearly 2,000 patients (some receiving
their first treatment for tuberculosis, some being re-treated)
with isoniazid mono-resistance. This meta-analysis showed
that lower relapse, failure, and acquired drug resistance rates
were associated with longer duration of rifampicin
treatment, use of streptomycin, daily therapy early in the
treatment, and regimens that included a greater number of
drugs to which the M. tuberculosis carried by the patient
were sensitive.
What Do These Findings Mean? These findings reveal
that there is very little published evidence that supports the
regimen currently recommended by WHO for the re-
treatment of tuberculosis. Furthermore, this limited body
of evidence is a patchwork of results gleaned from a few
cohort studies and a set of randomized trials not specifically
designed to test the efficacy of the standardized regimen.
There is an urgent need, therefore, for a concerted
international effort to initiate randomized trials of potential
treatment regimens in both previously untreated and
previously treated patients with all forms of drug-resistant
tuberculosis. Because these trials will take some time to
complete, the limited findings of the meta-analysis
presented here may be used in the meantime to redesign
and, hopefully, improve the current standardized re-
treatment regimen. In fact, the revised WHO TB treatment
guidelines will provide updated recommendations for
patients with previously treated TB.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000150.
N The results of another WHO-commissioned study into the
treatment of tuberculosis are presented in a separate PLoS
Medicine Research Article by Menzies et al. (Menzies D,
Benedetti A, Paydar A, Martin I, Royce S, et al. (2009) Effect
of Duration and Intermittency of Rifampin on Tuberculosis
Treatment Outcomes: A Systematic Review and Meta-
Analysis. PLoS Med 6(9): e1000146.)
N The US National Institute of Allergy and Infectious Diseases
provides information on all aspects of tuberculosis
N The American Thoracic Society, US Centers for Disease
Control and Prevention, and Infectious Diseases Society of
America offer guidelines on TB treatment
N The US Centers for Disease Control and Prevention provide
several facts sheets and other information resources about
tuberculosis
N The 2003 (2004 revision) WHO guidelines for national
programs for the treatment of tuberculosis are available;
WHO also provides information on efforts to reduce the
global burden of tuberculosis (in several languages) and its
2009 annual report on global control of tuberculosis
describes the current situation (key points are available in
several languages)
N The WHO publishes guidelines on TB treatment
N For guidelines on drug susceptibility testing (DST) and
other information on TB diagnostic tests, the Stop TB
Partnership’s New Diagnostics Working Group has created
a new Web site called Evidence-Based Tuberculosis
Diagnosis
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